Price gouging in the pharmaceutical industry has become a common feature of health news. Who can forget Martin Shkreli’s infamous price hike of the HIV drug Daraprim, which went from USD13.50 to $750 in the summer of 2015? Are international laws tough enough to ensure that the bottom line is the people and not profit?

Produced by: Tina Carmillia

Presented by: Meera Sivasothy

Download the BFM mobile app. Stay at home and stay up-to-date.

Tags:  international trade,  intellectual property,  access to medicine,  patent,  price control,  compulsory license,  cancer medicine,  drug prices,  sofosbuvir,  health and living,  the bigger picture,  Healthcare, Pharma, Biotech,  Health,  Health Policy,  Diseases and Conditions,  Mental Health,  Healthy Living,  Fitness,  Science,  Medical Innovation and Technology